Traws Pharma (TRAW) Stock Statistics & Valuation Metrics

Traws Pharma has a market cap or net worth of $22.57M. The enterprise value is $10.49M.

Traws Pharma has 15,150,669 shares outstanding. The number of shares has decreased by -2.65% in one year.

Traws Pharma’s return on equity (ROE) is -14.58 and return on invested capital (ROIC) is 3379.02%.

The current PE Ratio of Traws Pharma is ―. Traws Pharma’s PEG ratio is -0.00991.

In the last 12 months, Traws Pharma had revenue of 2.79M and earned 9.17M in profits. Earnings per share was 0.83.

In the last 12 months, operating cash flow was -2.58B and capital expenditures 0.00, giving a free cash flow of -2.58B billion.

Traws Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Traws Pharma upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).

Traws Pharma as a current ratio of 0.72, with Debt / Equity ratio of 0.00%

In the past 12 months, Traws Pharma has paid 0.00 in taxes.

Traws Pharma EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.26.

Traws Pharma has $3.13M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.13M billion.

Gross margin is 0.00%, with operating margin of -640.68%, and net profit margin of 328.67%.

The average price target for Traws Pharma is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy